MedPath

The Invia Motion at Cesarean Study

Phase 4
Completed
Conditions
Negative Pressure Wound Therapy
Cesarean Section; Infection
Interventions
Device: Invia Motion
Registration Number
NCT04365452
Lead Sponsor
Indiana University
Brief Summary

To assess patient centered outcomes of the Medela INVIA Motion prophylactic NPWT system at cesarean delivery.

Detailed Description

This study will be a two center case series of women undergoing caesarean delivery conducted at two medical centers in Indianapolis, Indiana.

All patients meeting inclusion criteria will be included. All enrolled patients will receive the Medela INVIA Motion prophylactic NPWT device.

Visit A: Interventional Procedure All enrolled patients will receive the Medela INVIA Motion device placed by the patient's surgeon after the skin is closed with subcuticular suture or staples. Research staff and clinicians (labor \& delivery and postpartum nurses, OR technicians, physicians, etc.) involved in the study will receive formal training on how to place and remove the prophylactic NPWT device.

Visit B: Post Procedure until Discharge Patients will be monitored daily while in the hospital by clinical staff and/or research staff for complications.

The negative pressure wound therapy dressing will be removed on the day of discharge. If the patient remains hospitalized for more than 7 days, the dressing will be removed on postoperative day 7.

Replacement of any dressing that is saturated. If a patient develops infection with the NPWT device in place the device will be removed and the patient given standard SSI therapy as outlined below.

Patients will be educated about the signs and symptoms of infection and other study outcomes and encouraged to call their provider if these should arise.

Research staff document inpatient course regarding SSI. Management of surgical site infections will follow the Practice Guidelines of the Infectious Diseases Society of America.

Visit C: Postpartum Follow Up

We will use active surveillance by research staff to ascertain surgical site infections:

Research staff will follow-up with the research participant at time of discharge or within 48 hours post discharge (postpartum day 1-9) to assess for adverse events, assess the participant's pain, obtain their satisfaction with their dressing and aesthetic appearance of the incision.

Research staff will call subjects on approximately postoperative day 30 (±2 days). They will ask the patient standardized questions regarding wound complications, patient satisfaction, pain and aesthetic appearance. If the patient reports a hospital, clinic, or ER visit not associated with the study centers, the staff will obtain the name of the medical facility and request the records.

The EQ-5D-3L quality of life questionnaire will be administered at the 30-day call.

Medical records from postpartum clinic visits as well as records of unscheduled visits (to any hospital clinic or ER) will be sought to ascertain study outcomes.

At the time of the subject's standard of care postpartum appointment about 4-6 weeks after inpatient hospital discharge research staff will collect information on outcomes, pain and patient satisfaction. If the patient does not attend the clinical postpartum visit, the study staff will contact the subject by phone to collect the data.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  1. Scheduled/non-labor or unscheduled/labor cesarean delivery
  2. Gestational age greater than or equal to 23 weeks
Read More
Exclusion Criteria
  1. Unwilling or unable to provide consent
  2. Non-availability for postoperative follow-up
  3. Contraindication to NPWT
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Invia Motion ArmInvia Motion-
Primary Outcome Measures
NameTimeMethod
Patient Satisfaction With Aesthetic Appearance: ScaleAt postoperative day 30 (+/- 2 days)

Patient satisfaction with aesthetic appearance (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Pain Scores: Discharge Time FrameAt post-operative day 3 (+/- 1 days)

Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

Patient Satisfaction: Scores Discharge Time FrameAt postoperative day 3 (+/- 1 days)

Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Pain Scores: Scores Postpartum Day 30At postoperative day 30 (+/- 2 days)

Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

Patient Satisfaction: Scores Postpartum Day 30At postoperative day 30 (+/- 2 days)

Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Secondary Outcome Measures
NameTimeMethod
Wound Separation; Proportion of Incidence4-6 Weeks Postpartum

Composite wound complication; wound separation as diagnosed by treating clinician

Allergic Reaction; Safety Outcomes4-6 Weeks Postpartum

Safety outcome; proportion of allergic reaction to wound dressing

Wound Bleeding; Safety Outcomes4-6 Weeks Postpartum

Safety outcome; proportion of wound bleeding

Antibiotics Prescribed for Presumed SSI; Proportion of Incidence4-6 Weeks Postpartum

Composite wound complication; antibiotics prescribed by treating clinician for wound-related infection

Skin Blistering; Safety Outcomes4-6 Weeks Postpartum

Safety outcome; proportion of incidence of skin blistering around surgical wound

Wound Infection; Proportion of Incidence4-6 Weeks Postpartum

Composite wound complication; wound infection as diagnosed by treating clinician

Seroma; Proportion of Incidence4-6 Weeks Postpartum

Composite wound complication; seroma as diagnosed by treating clinician

Trial Locations

Locations (1)

Indiana University

🇺🇸

Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath